CJC-1295 no Dac 10mg
Janoshik
Batch CJND-CA-26F-10
CJC-1295 (No DAC)
GHRH Analogue Research Peptide
CJC-1295 (No DAC) is commonly studied for its role in stimulating short-acting growth hormone signaling and mimicking natural pulsatile GH release patterns in research models. It is often explored for its effects on recovery processes, tissue maintenance, and metabolic regulation within controlled laboratory settings.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
CJC-1295 (No DAC) is a synthetic peptide analogue of growth hormone–releasing hormone (GHRH) developed for controlled laboratory research. The “No DAC” designation indicates the absence of a drug affinity complex, resulting in a shorter receptor interaction profile within experimental systems.
In scientific literature, CJC-1295 (No DAC) is studied in models examining GHRH receptor activation, hypothalamic-pituitary signaling pathways, and downstream endocrine regulatory mechanisms under in vitro and preclinical research conditions.
Third-party tested for purity, identity, quantity.
CJC-1295 (No DAC) is a modified GHRH analogue evaluated in research focused on growth hormone–releasing hormone receptor activity and endocrine signaling systems. Experimental studies examine receptor-binding dynamics, hypothalamic-pituitary axis interaction models, and regulated peptide signaling pathways within controlled laboratory environments.
Research publications have explored its receptor interaction profile and downstream growth hormone–associated signaling mechanisms under structured study conditions.
CJC-1295 was developed during investigations into stabilized GHRH analogues designed to enhance receptor interaction and signaling characteristics. Variants were created with and without a drug affinity complex (DAC), allowing comparative study of duration and receptor interaction properties.
Subsequent research documented its signaling profile within endocrine pathway research frameworks.
Laboratory investigations into CJC-1295 (No DAC) have focused on GHRH receptor activation models and downstream endocrine signaling pathways. Research frameworks evaluate receptor-mediated interaction, hypothalamic-pituitary axis dynamics, and regulated peptide response systems under controlled in vitro and preclinical conditions.
0 of the 4 areas below are addressed directly by a paper cited on this page.
GHRH receptor activation models
No paper cited on this page reports on ghrh, receptor or activation. This heading marks where CJC-1295 (No DAC) is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Hypothalamic-pituitary signaling studies
No paper cited on this page reports on hypothalamic or pituitary. This heading marks where CJC-1295 (No DAC) is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Endocrine regulatory pathway research
No paper cited on this page reports on endocrine. This heading marks where CJC-1295 (No DAC) is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Stabilized peptide analogue evaluation
No paper cited on this page reports on stabilized, peptide or analogue. This heading marks where CJC-1295 (No DAC) is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 1 primary paper published in 2006 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for CJC-1295 (No DAC), set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
CJC-1295 (No DAC) is also referred to as mod GRF 1-29, CJC without DAC.
CJC-1295 (No DAC) is commonly described online in connection with muscle growth, fat loss and improved recovery. In the research literature the same compound is filed under GHRH receptor activation models, hypothalamic-pituitary signaling studies and endocrine regulatory pathway research.
The 1 paper cited on this page, published in 2006 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Presented alongside compounds with decades of published research, as though the evidence base is comparable.
It is not. CJC-1295 (No DAC) rests on 1 cited paper (in 2006). A record that thin cannot support conclusions about mechanism, effect or safety, and the honest reading is that this compound has been studied very little rather than studied and validated.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for CJC-1295 (No DAC) is per lot, not per product. The current 10mg lot CJND-CA-26F-10 returned 99.777% purity, 10.76 mg measured, 107.6% of the labelled 10 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is CJC-1295 (No DAC); it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for CJC-1295 (No DAC), this lot measured 107.6% of its labelled 10 mg. Both numbers are published for every lot, whichever way they fall.
The lot code printed on the vial matches the code on the certificate for CJC-1295 (No DAC). Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy CJC-1295 (No DAC) in the United States through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
CJC-1295 (No DAC) is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 29 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (10mg / Single Vial, 10mg / 5-Pack, 10mg / 10-Pack available), batch-labelled
- The batch-linked Certificate of Analysis for the exact lot shipped
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 10mg of lyophilized CJC-1295 (No DAC). Independent third-party testing verifies purity, identity, and net content per batch.
The vial contains only the peptide preparation. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone–releasing hormone, in healthy adults.
PubMedRelated
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
From$79.99
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$39.99
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$59.99
Long-acting amylin analog engineered for appetite signaling, metabolic control, and energy balance research
From$99.99